A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
about
Which anticholinergic drug for overactive bladder symptoms in adultsPersistence and compliance with medication management in the treatment of overactive bladderTotal urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptomsTrospium chloride treatment of overactive bladderSolifenacin significantly improves all symptoms of overactive bladder syndrome.Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments.Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainDose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinenceBehavioral treatment of insomnia: also effective for nocturia.Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry.AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.Medical management of overactive bladderContent validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder.Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Muscarinic receptors in the bladder: from basic research to therapeutics.[Anticholinergics for overactive bladder: does subtype selectivity play a role?]Tolterodine extended-release for overactive bladder.Emerging drugs for treatment of urinary incontinence.Muscarinic receptor antagonists for overactive bladder.An overview of the clinical use of antimuscarinics in the treatment of overactive bladderCurrent trends in the evaluation and management of female urinary incontinence.Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)Combination therapies for the management of nocturia and its comorbiditiesM2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors.The Relations between Enuresis in Childhood and Nocturnal Polyuria Syndrome in Adult LifeEffects of a Gentle, Self-Administered Stimulation of Perineal Skin for Nocturia in Elderly Women: A Randomized, Placebo-Controlled, Double-Blind Crossover Trial.Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms.Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent.Current and emerging investigational medical therapies for the treatment of overactive bladder.Overactive bladder: The importance of new guidance.Urinary incontinence: economic burden and new choices in pharmaceutical treatment.Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.Overactive bladder syndrome in older people.Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?A review of solifenacin in the treatment of urinary incontinence.Management of overactive bladder syndromeA practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting.How to choose the initial drug treatment for overactive bladder.
P2860
Q24203880-37F89D74-CD4C-4991-AA63-D3923671F581Q26765014-AE5EE6E1-17DA-459B-8110-4665B33C1D9EQ27001248-ECA904CA-0CD8-4961-A82E-BA5DC0C53C16Q28308162-C9BCB96E-8F93-4F29-AD38-E90AFE6C3B12Q30445725-BF69C9A6-B409-47F1-B572-F8073C14490BQ31095754-145AF94E-27DB-45E2-96E1-DEEE224F9E45Q33560320-03DA3A87-3DAE-46A3-99E3-74EB6A001546Q33588346-39FD0FFB-634D-4DA4-939C-651048D86473Q33692394-2E286E8F-FF4D-450D-B880-78A4A3677514Q33748111-9E24DCD1-7E2D-4EB2-B62A-CEB1BF71F6BDQ34077022-E19D74E6-776F-4479-9E51-F08C5FEBB8E2Q34112974-69FC75EB-DB23-4D15-A7F1-FC2CBE8C9E48Q34124065-D9F52A76-D2F2-4854-A4C4-F7F4E47B26B6Q34408830-BF44754D-2C3F-4B00-9443-FF116D79C972Q34502903-E6B3AF24-539D-4A54-81ED-A5595E6013ABQ34564708-7B8269C6-F083-4D8C-AF59-F5384232788EQ34568286-AEC2DBA7-4893-4F67-ADEE-E3C552E32667Q34610640-0DCE242B-6234-4A1D-99AF-75D442B18AECQ34618648-35401ADE-4157-4B20-9682-E61B5FDCA9B2Q34699525-B2429227-42C0-4812-98EA-59CDFEBDC017Q35042575-49657759-395C-4734-B354-BA67CCBA09CCQ35113508-06EF8CC1-7FBB-4DE1-9D16-EFE842AE8EDFQ35419834-73290AAC-0C81-46B9-9FEE-0C09DB54953EQ35535376-AFFC9A0C-0203-447D-B645-2CBEB9CDD567Q35801020-11DA5436-2638-4D80-9B5A-510978C3E8CAQ35875556-0214A65D-6761-41A0-B802-C6C67EF699B0Q35966051-A1869612-0976-4777-8692-E10FAFA3DE19Q36239162-1B375DD2-BCDA-4F09-B535-CAD40BA8A59FQ36428481-E49C9BCA-F44C-4AB0-8E6B-C30E31A69B76Q36563410-CDE03AED-7B2E-4B55-87BB-01C30F873166Q36568728-282905DB-061C-4569-A215-A01D3105CFC4Q36596773-AEC1A124-4446-42E6-838C-FEB9AD728AA8Q36627923-1715A5D5-54D1-4654-81F6-239B53AA5767Q36655193-9EE97F25-0890-4B0D-8A74-C62C5978BC3FQ36779724-8A99A2C9-85D9-410E-B37F-BEACC30E0B73Q36815273-125DBFE6-9579-4C10-B0B2-F91220AD264BQ36822864-E475C1D4-A257-44BF-AA3A-26E796B8E347Q36875672-BB2B3BA3-AE30-40AF-B6F5-E697540E8532Q36879656-4006D3FD-FA3F-4F15-9929-6A5EE050D401Q36946067-7CCEBF79-EB12-4873-8941-209D57BB49DD
P2860
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A comparison of the efficacy a ...... me: results of the STAR trial.
@en
A comparison of the efficacy a ...... me: results of the STAR trial.
@nl
type
label
A comparison of the efficacy a ...... me: results of the STAR trial.
@en
A comparison of the efficacy a ...... me: results of the STAR trial.
@nl
prefLabel
A comparison of the efficacy a ...... me: results of the STAR trial.
@en
A comparison of the efficacy a ...... me: results of the STAR trial.
@nl
P2093
P1433
P1476
A comparison of the efficacy a ...... me: results of the STAR trial.
@en
P2093
D M Wright
J Bolodeoku
L Selvaggi
R Martinez-Garcia
STAR study group
T Drogendijk
P304
P356
10.1016/J.EURURO.2005.05.015
P407
P577
2005-09-01T00:00:00Z